Long-term treatment with imidapril but not with nifedipine enhances plasma NOx concentration in patients with essential hypertension

Journal of Pharmacological Sciences

Volumn 101, Issue 2, 2006, Pages 159-165

  Suda, Osamu ^a,c   Tsutsui, Masato ^a,b   Morishita, Tsuyoshi ^a   Horiuchi, Masataka ^a   Nakata, Sei ^a   Kouzuma, Ryouji ^a   Okazaki, Masahiro ^a   Sumiyama Fujinishi, Akiko ^b   Mizuki, Tsunetaka ^b   Yanagihara, Nobuyuki ^a   Tasaki, Hiromi ^a   Nakashima, Yasuhide ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Moji Rosai Hospital   (Japan)

^c CENTRAL JAPAN RAILWAY COMPANY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Calcium channel antagonist; Human; Hypertension; Nitric oxide

Indexed keywords

BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; NIFEDIPINE; NITRIC OXIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LONG TERM CARE; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 33745322322     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0060031     Document Type: Article

References (42)

1. Bredt DS, Snyder SH. Nitric oxide: a physiological messenger molecule. Annu Rev Biochem. 1994;63:175-195.
2. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153-2157.
3. Luscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, FL: CRC Press; 1990.
4. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest. 1998;102:2061-2071.
5. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
6. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
7. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet. 1997;349:837-842.
8. Luscher TF. Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension? Am J Hypertens. 1990;3:317-330.
9. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989;86:3375-3378.
10. Kawashima S. Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis. J Pharmacol Sci. 2004;96:411-419.
11. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
12. Takase H, Sugiyama M, Nakazawa A, Sato K, Ueda R, Dohi Y. Long-term effect of antihypertensive therapy with calcium antagonist or angiotensin converting enzyme inhibitor on serum nitrite/nitrate levels in human essential hypertension. Arzneimittelforschung. 2000;50:530-534.
13. Di Girolamo G, Gonzalez E, Livio D, de los Santos AR, Marti ML, de Gimeno MA. The effect of Enalapril on PGI(2) and NO levels in hypertensive patients. Prostaglandins Leukot Essent Fatty Acids. 2002;66:493-498.
14. Kohno M, Yokokawa K, Minami M, Yasunari K, Maeda K, Kano H, et al. Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension. Metabolism. 1999;48:1256-1259.
15. Saruta T, Arakawa K, Iimura O, Abe K, Matsuoka H, Nakano T, et al. Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res. 1999;22:197-202.
16. - levels in patients with hypercholesterolemia. Atherosclerosis. 1996;127:43-47.
17. Suda O, Tsutsui M, Morishita T, Tanimoto A, Horiuchi M, Tasaki H, et al. Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation. 2002;106:1729-1735.
18. Kasahara Y, Ashihara Y. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem. 1981;27:1922-1925.
19. Morishita T, Tsutsui M, Shimokawa H, Tasaki H, Suda O, Kobayashi K, et al. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol. 2002;88:100-107.
20. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29:242-247.
21. Higuchi K, Motomizu S. Flow-injection spectrophotometric determination of nitrite and nitrate in biological samples. Analytical Sciences. 1999;15:129-134.
22. Ishibashi T, Yoshida J, Nishio M. New methods to evaluate endothelial function: A search for a marker of nitric oxide (NO) in vivo: re-evaluation of NOx in plasma and red blood cells and a trial to detect nitrosothiols. J Pharmacol Sci. 2003;93:409-416.
23. Ellis G, Adatia I, Yazdanpanah M, Makela SK. Nitrite and nitrate analyses: a clinical biochemistry perspective. Clin Biochem. 1998;31:195-220.
24. Tanaka S, Yashiro A, Nakashima Y, Nanri H, Ikeda M, Kuroiwa A. Plasma nitrite/nitrate level is inversely correlated with plasma low-density lipoprotein cholesterol level. Clin Cardiol. 1997;20:361-365.
25. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension. 1997;30:405-408.
26. Cittadino M, Goncalves de Sousa M, Ugar-Toledo JC, Rocha JC, Tanus-Santos JE, Moreno H Jr. Biochemical endothelial markers and cardiovascular remodeling in refractory arterial hypertension. Clin Exp Hypertens. 2003;25:25-33.
27. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A. 2001;98:12814-12819.
28. Morishita T, Tsutsui M, Shimokawa H, Sabanai K, Tasaki H, Suda O, et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci U S A. 2005;102:10616-10621.
29. De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, et al. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. Eur J Pharmacol. 2005;516:253-259.
30. Wen C, Li M, Fraser T, Wang J, Turner SW, Whitworth JA. Larginine partially reverses established adrenocorticotrophin-induced hypertension and nitric oxide deficiency in the rat. Blood Press. 2000;9:298-304.
31. Higashi Y, Oshima T, Sasaki S, Nakano Y, Kambe M, Matsuura H, et al. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension. Hypertension. 1998;32:16-24.
32. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003;59:824-833.
33. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-2037.
34. Vanhoutte PM, Boulanger CM, Illiano SC, Nagao T, Vidal M, Mombouli JV. Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol. 1993;22 Suppl 5:S10-S16.
35. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond). 1994;87:567-574.
36. Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J. 1998;19:J7-J15.
37. Nakashima M, Mombouli JV, Taylor AA, Vanhoutte PM. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest. 1993;92:2867-2871.
38. Pelc LR, Gross GJ, Warltier DC. Mechanism of coronary vasodilation produced by bradykinin. Circulation. 1991;83:2048-2056.
39. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
40. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation. 2003;108:2034-2040.
41. Jackson EK. Inhibitors of the renin-angiotensin system. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw Hill; 2006. p. 800-810.
42. Nagasaki M, Tsutsui M, Shimokawa H, Morishita T, Nakata S, Sabanai K, et al. Spontaneous development of systemic arteriosclerosis in mice lacking all nitric oxide synthase isoforms. Circulation. 2005;112:II-166.